Workflow
乐普医疗:获得《药物临床试验批准通知书》

Group 1 - Lepu Medical announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for clinical trials of its self-developed injectable recombinant type A botulinum toxin [1] - The revenue composition for Lepu Medical in 2024 is projected to be 54.5% from medical devices, 28.8% from pharmaceuticals, and 16.7% from medical services and health management [1]